Author Interviews, Cost of Health Care, Heart Disease, JACC / 26.02.2023
Inflation Reduction Act: Implications on Out-Of-Pocket Costs for Patients with Heart Disease Risk Factors
MedicalResearch.com Interview with:
Rishi K. Wadhera, MD, MPP, MPhil
Section Head, Health Policy and Equity,
Richard A. and Susan F. Smith Center for Outcomes Research
Associate Program Director
Cardiovascular Medicine Fellowship at Beth Israel Deaconess Medical Center
Assistant Professor of Medicine,
Harvard Medical School
@rkwadhera
MedicalResearch.com: What is the background for this study?
Response: High and rising prescription drug costs in the United States contribute to medication non-adherence and financial strain among adults with cardiovascular risk factors or disease. As a result, addressing prescription drug costs in patients with chronic conditions has become a national priority.
In response to these growing concerns, federal policymakers passed the Inflation Reduction Act on August 16, 2022, which aims to address high out-of-pocket drug costs for adults enrolled in Medicare Part D, by placing a $2000 annual cap on out-of-pocket prescription drug costs and expanding eligibility for full low-income subsidies to individuals that reduce deductible costs and prescription copayments (among several other provisions). It is unclear how these provisions will affect Medicare beneficiaries with cardiovascular risk factors and/or conditions.
(more…)